1 / 135

NOTICE:

CITR Annual Report Exhibits Prepared by: CITR Coordinating Center The EMMES Corporation Rockville, MD Sponsored by: National Institute of Diabetes & Digestive & Kidney Diseases National Institutes of Health Bethesda, MD. NOTICE:

donagh
Download Presentation

NOTICE:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CITR Annual ReportExhibitsPrepared by:CITR Coordinating CenterThe EMMES CorporationRockville, MDSponsored by:National Institute of Diabetes & Digestive & Kidney DiseasesNational Institutes of HealthBethesda, MD

  2. NOTICE: The CITR Annual Report details data received as of April 5, 2004 for all islet transplant recipients registered by November 30, 2003. These data should be considered a privileged communication and may not be used for publication or presentation without prior written permission of the CITR Publications/Presentations Committee.

  3. Contributing Islet Transplant Centers

  4. SECTION 1:Islet Transplant Recipient and Donor Characteristics

  5. Total Number of Infusion Procedures Conductedby Year and by Infusion Sequence 99 pancreata were used for first infusion procedures 59 pancreata were used for second infusion procedures 15 pancreata were used for third infusion procedures

  6. Recipient Demographics by Year of First Infusion

  7. Recipient Characteristics by Year of First Infusion

  8. Recipient Characteristics by Year of First Infusion(continued)

  9. Recipient’s Primary Payer and Employment Status at Time of Infusionby Infusion Sequence

  10. Recipient’s Primary Payer and Employment Status at Time of Infusionby Year of Infusion

  11. Recipient Status at First Infusion

  12. Recipient Status at First Infusion(continued)

  13. Recipient Status at First Infusion(continued)

  14. Recipient’s Body Mass Index by Infusion Sequence

  15. Secondary Complications at Recipient’s First Infusion

  16. Number of Secondary Complications Reported at Recipient’s First Infusion

  17. Ocular Complications at Recipient’s First Infusion

  18. Infusion Summary by Infusion Sequence

  19. Infusion Characteristics by Infusion Sequence

  20. Deceased Donor Characteristics(All Donors, N=173)

  21. Deceased Donor Characteristics

  22. Deceased Donor Characteristics (continued)

  23. Deceased Donor Characteristics (continued)

  24. Deceased Donor Characteristics (continued)

  25. Deceased Donor Age (yrs)

  26. Deceased Donor Weight (kg)

  27. Deceased Donor Height (m)

  28. Deceased Donor Body Mass Index

  29. Time from Admission to Brain Death (hrs)

  30. Time from Cross Clamp to Pancreas Recovery (mins)

  31. Deceased Donor Characteristics: Use of Vasopressors(All Donors, N=173)

  32. Deceased Donor Serology

  33. Recipient Serology at Screening

  34. Changes in Serology Results from Screening to Post First Infusion(N=57)

  35. Deceased Donor Laboratory Data(All Donors, N=173)

  36. Deceased Donor Serum Creatinine (mg/dL)

  37. Deceased Donor BUN (mg/dL)

  38. Deceased Donor Total Bilirubin (mg/dL)

  39. Deceased Donor AST (IU/L)

  40. Deceased Donor ALT (IU/L)

  41. Deceased Donor Serum Lipase (IU/L)

  42. Deceased Donor Serum Amylase (IU/L)

  43. SECTION 2:Pancreas Procurement andIslet Processing

  44. Pancreas Procurement Information by Year of Infusion

  45. Islet Processing Summary by Year

  46. Islet Processing Summary by Year(continued)

  47. Summary of Islet Equivalents and Timing of Count

  48. Islet Product Characterization(All Pancreata, N=173)

  49. Islet Product Characterization(All Pancreata, N=173)(continued)

  50. Total Islet Equivalents by Cold Ischemic Time(All Pancreata)

More Related